Description

A study by StrategyHelix indicates that the global dry age-related macular degeneration market is expected to increase by US$ 1.7 billion from 2022 to 2028, garnering a CAGR of 7.1% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for dry age-related macular degeneration. The global dry age-related macular degeneration market is segmented on the basis of category, stage, age group, route of administration, end user, and region. Based on category, the global dry age-related macular degeneration market is categorized into diagnosis, treatment. On the basis of stage, the global dry age-related macular degeneration market has been segmented into early AMD, intermediate AMD, late AMD. By age group, the global dry age-related macular degeneration market has been segmented into above 40 years, above 60 years, above 75 years. Based upon route of administration, the global dry age-related macular degeneration market is categorized into injectables, oral. On the basis of end user, the global dry age-related macular degeneration market has been segmented into academic research institutes, diagnostic centers, hospitals & clinics, others. In terms of geography, the global dry age-related macular degeneration market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global dry age-related macular degeneration market is highly competitive. Some of the leading companies operating in the market are Alimera Sciences Inc., Allergan plc (AbbVie Inc.), Bausch Health Companies Inc., Belite Bio Inc, Eyestem Research Private Limited, IVERIC bio Inc., Kubota Pharmaceutical Holdings Co. Ltd., Ocumension Therapeutics Ltd., Phio Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Stealth BioTherapeutics Corp., YUYANG DNU Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the dry age-related macular degeneration market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Category: diagnosis, treatment
Stage: early AMD, intermediate AMD, late AMD
Age group: above 40 years, above 60 years, above 75 years
Route of administration: injectables, oral
End user: academic research institutes, diagnostic centers, hospitals & clinics, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global dry age-related macular degeneration market
– Identify regional strategies and strategic priorities on the basis of local data
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Dry age-related macular degeneration market overview
Part 3. Market breakdown by category
– Diagnosis
– Treatment
Part 4. Market breakdown by stage
– Early AMD
– Intermediate AMD
– Late AMD
Part 5. Market breakdown by age group
– Above 40 years
– Above 60 years
– Above 75 years
Part 6. Market breakdown by route of administration
– Injectables
– Oral
Part 7. Market breakdown by end user
– Academic research institutes
– Diagnostic centers
– Hospitals & clinics
– Others
Part 8. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 9. Key companies
– Alimera Sciences, Inc.
– Allergan plc (AbbVie Inc.)
– Bausch Health Companies Inc.
– Belite Bio, Inc
– Eyestem Research Private Limited
– IVERIC bio, Inc.
– Kubota Pharmaceutical Holdings Co., Ltd.
– Ocumension Therapeutics Ltd.
– Phio Pharmaceuticals Inc.
– Santen Pharmaceutical Co., Ltd.
– Stealth BioTherapeutics Corp.
– YUYANG DNU Co., Ltd.
About StrategyHelix
Disclaimer